Global InformationVonicog alfa information
| Clinical data | |
|---|---|
| Trade names | Vonvendi, Veyvondi |
| Other names | BAX-111 |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Intravenous |
| Drug class | Hemostatic |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number |
|
| DrugBank |
|
| UNII |
|
| KEGG |
|
| Chemical and physical data | |
| Formula | C9712H15373N2737O3032S210 |
| Molar mass | 225725.54 g·mol−1 |
Vonicog alfa, sold under the brand names Vonvendi and Veyvondi, is a medication used to control bleeding in adults with von Willebrand disease (an inherited bleeding disorder).[6][5][7][8] It is a recombinant von Willebrand factor.[6][5]
The most common adverse reactions are generalized itching, vomiting, nausea, dizziness, and vertigo.[6]
Vonicog alfa should not be used in the treatment of Hemophilia A.[5]
In the UK it is available only via a named patient access program.[9]
Vonicog alfa was approved for medical use in the United States in December 2015, in the European Union in August 2018, and in Australia in April 2020.[4][6][5][10] It was granted orphan drug designations in both the United States and the European Union.[5][1]
- ^ a b c "Veyvondi Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 29 April 2020. Retrieved 16 August 2020.
- ^ "Summary Basis of Decision (SBD) for Vonvendi". Health Canada. 23 October 2014. Retrieved 29 May 2022.
- ^ "Vonvendi 650 IU powder and solvent for solution for injection - Summary of Product Characteristics (SmPC)". (emc). 7 May 2020. Retrieved 16 August 2020.
- ^ a b "Vonvendi". U.S. Food and Drug Administration (FDA). 9 May 2018. Archived from the original on 23 April 2019. Retrieved 15 April 2020.
{{cite web}}: CS1 maint: unfit URL (link) - ^ a b c d e f "Veyvondi EPAR". European Medicines Agency (EMA). 20 September 2018. Retrieved 27 March 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ a b c d "Vonvendi (von willebrand factor- recombinant kit". DailyMed. 13 February 2019. Retrieved 27 March 2020.
- ^ "Veyvondi-epar product information" (PDF). European Medicines Agency.
- ^ Tran T, Arnall J, Moore DC, Ward L, Palkimas S, Man L (April 2020). "Vonicog alfa for the management of von Willebrand disease: a comprehensive review and single-center experience". Journal of Thrombosis and Thrombolysis. 49 (3): 431–440. doi:10.1007/s11239-019-02018-1. PMID 31902122. S2CID 209673044.
- ^ "Vonicog alfa". Specialist Pharmacy Service. 15 January 2020. Archived from the original on 27 March 2020. Retrieved 27 March 2020.
- ^ "Vonvendi". U.S. Food and Drug Administration (FDA). 13 April 2018. STN: 125577. Retrieved 27 March 2020.